| 1 |
Devergne O, Birkenbach M, Kieff E. Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin [J]. Proc Natl Acad Sci U S A, 1997, 94(22): 12041-12046.
|
| 2 |
Shen P, Roch T, Lampropoulou V, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases [J]. Nature, 2014, 507(7492): 366-370.
|
| 3 |
Wang RX, Yu CR, Dambuza IM, et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease [J]. Nat Med, 2014, 20(6): 633-641.
|
| 4 |
Olson BM, Jankowska-Gan E, Becker JT, et al. Human prostate tumor antigen-specific CD8＋ regulatory T cells are inhibited by CTLA-4 or IL-35 blockade [J]. J Immunol, 2012, 189(12): 5590-5601.
|
| 5 |
Pflanz S, Timans JC, Cheung J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4＋ T cells [J]. Immunity, 2002, 16(6): 779-790.
|
| 6 |
Jones LL, Chaturvedi V, Uyttenhove C, et al. Distinct subunit pairing criteria within the heterodimeric IL-12 cytokine family [J]. Mol Immunol, 2012, 51(2): 234-244.
|
| 7 |
Long J, Zhang X, Wen M, et al. IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells [J]. Biochem Biophys Res Commun, 2013, 430(1): 364-369.
|
| 8 |
Wang Z, Liu JQ, Liu Z, et al. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis [J]. J Immunol, 2013, 190(5): 2415-2423.
|
| 9 |
Li X, Mai J, Virtue A, et al. IL-35 is a novel responsive anti-inflammatory cytokine--a new system of categorizing anti-inflammatory cytokines [J]. PLoS One, 2012, 7(3): e33628.
|
| 10 |
Collison LW, Chaturvedi V, Henderson AL, et al. IL-35-mediated induction of a potent regulatory T cell population [J]. Nat Immunol, 2010, 11(12): 1093-1101.
|
| 11 |
Guo H, Zhao N, Gao H, et al. Mesenchymal stem cells overexpressing interleukin-35 propagate immunosuppressive effects in mice [J]. Scand J Immunol, 2017, 86(5): 389-395.
|
| 12 |
Du WX, He Y, Jiang HY, et al. Interleukin 35: A novel candidate biomarker to diagnose early onset sepsis in neonates [J]. Clin Chim Acta, 2016, 462: 90-95.
|
| 13 |
Collison LW, Workman CJ, Kuo TT, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function [J]. Nature, 2007, 450(7169): 566-569.
|
| 14 |
Wirtz S, Billmeier U, McHedlidze T, et al. Interleukin-35 mediates mucosal immune responses that protect against T-cell-dependent colitis [J]. Gastroenterology, 2011, 141(5): 1875-1886.
|
| 15 |
Zhang B, Liu Y, Lan X, et al. Oral Escherichia coli expressing IL-35 meliorates experimental colitis in mice [J]. J Transl Med, 2018, 16(1): 71.
|
| 16 |
Yan Y, Zhao N, He X, et al. Mesenchymal stem cell expression of interleukin-35 protects against ulcerative colitis by suppressing mucosal immune responses [J]. Cytotherapy, 2018, 20(7): 911-918.
|
| 17 |
Li Y, Wang Y, Liu Y, et al. The possible role of the novel cytokines il-35 and il-37 in inflammatory bowel disease [J]. Mediators Inflamm, 2014, 2014: 136329.
|
| 18 |
Mohammadnia-Afrouzi M, Hosseini AZ, Khalili A, et al. Altered microRNA Expression and Immunosuppressive Cytokine Production by Regulatory T Cells of Ulcerative Colitis Patients [J]. Immunol Invest, 2016, 45(1): 63-74.
|
| 19 |
Fonseca-Camarillo G, Furuzawa-Carballeda J, Yamamoto-Furusho JK. Interleukin 35 (IL-35) and IL-37: Intestinal and peripheral expression by T and B regulatory cells in patients with Inflammatory Bowel Disease [J]. Cytokine, 2015, 75(2): 389-402.
|
| 20 |
Mansour AI, Abd Almonaem ER, Behairy OG, et al. Predictive value of IL-35 and IL-17 in diagnosis of childhood asthma [J]. Scand J Clin Lab Invest, 2017: 1-6.
|
| 21 |
Wang W, Li P, Yang J. Decreased circulating interleukin-35 levels are related to interleukin-4-producing CD8＋T cells in patients with allergic asthma [J]. Iran J Allergy Asthma Immunol, 2015, 14(4): 379-385.
|
| 22 |
Ma Y, Liu X, Wei Z, et al. The expression of a novel anti-inflammatory cytokine IL-35 and its possible significance in childhood asthma [J]. Immunol Lett, 2014, 162(1 Pt A): 11-17.
|
| 23 |
Chen C, Deng Y, Chen H, et al. Decreased concentration of IL-35 in plasma of patients with asthma and COPD [J]. Asian Pac J Allergy Immunol, 2014, 32(3): 211-217.
|
| 24 |
Ding LF, Chen Q, Li L, et al. [Effects of sublingual immunotherapy on serum IL-17 and IL-35 levels in children with allergic rhinitis or asthma] [J]. Zhongguo Dang Dai Er Ke Za Zhi, 2014, 16(12): 1206-1210.
|
| 25 |
Khoshkhui M, Alyasin S, Sarvestani EK, et al. Evaluation of serum interleukin-35 level in children with persistent asthma [J]. Asian Pac J Allergy Immunol, 2017, 35(2): 91-95.
|
| 26 |
Wong CK, Leung TF, Chu IM, et al. Aberrant expression of regulatory cytokine IL-35 and pattern recognition receptor NOD2 in patients with allergic asthma [J]. Inflammation, 2015, 38(1): 348-360.
|
| 27 |
Li Y, Pan X, Peng X, et al. Adenovirus-mediated interleukin-35 gene transfer suppresses allergic airway inflammation in a murine model of asthma [J]. Inflamm Res, 2015, 64(10): 767-774.
|
| 28 |
Li Y, Wu S, Li Y, et al. Interleukin-35 (IL-35) inhibits proliferation and promotes apoptosis of fibroblast-like synoviocytes isolated from mice with collagen-induced arthritis [J]. Mol Biol Rep, 2016, 43(9): 947-956.
|
| 29 |
Niedbala W, Wei XQ, Cai B, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells [J]. Eur J Immunol, 2007, 37(11): 3021-3029.
|
| 30 |
Kochetkova I, Golden S, Holderness K, et al. IL-35 stimulation of CD39＋ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10 [J]. J Immunol, 2010, 184(12): 7144-7153.
|
| 31 |
Nakano S, Morimoto S, Suzuki S, et al. Immunoregulatory role of IL-35 in T cells of patients with rheumatoid arthritis [J]. Rheumatology (Oxford), 2015, 54(8): 1498-1506.
|
| 32 |
Hu L, Chen C, Zhang J, et al. IL-35 pretreatment alleviates lipopolysaccharide-induced acute kidney injury in mice by inhibiting NF-kappaB activation [J]. Inflammation, 2017, 40(4): 1393-1400.
|
| 33 |
Cao J, Xu F, Lin S, et al. IL-35 is elevated in clinical and experimental sepsis and mediates inflammation [J]. Clin Immunol, 2015, 161(2): 89-95.
|
| 34 |
Cai Z, Wong CK, Dong J, et al. Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice [J]. Clin Exp Immunol, 2015, 181(2): 253-266.
|
| 35 |
Sonmez C, Yucel AA, Yesil TH, et al. Correlation between IL-17A/F, IL-23, IL-35 and IL-12/-23 (p40) levels in peripheral blood lymphocyte cultures and disease activity in Behcet′s patients [J]. Clin Rheumatol, 2018, 37(10): 2797-2804.
|
| 36 |
Jafarzadeh A, Jamali M, Mahdavi R, et al. Circulating levels of interleukin-35 in patients with multiple sclerosis: evaluation of the influences of FOXP3 gene polymorphism and treatment program [J]. J Mol Neurosci, 2015, 55(4): 891-897.
|
| 37 |
Liu B, Zhao H, Poon MC, et al. Abnormality of CD4＋CD25＋ regulatory T cells in idiopathic thrombocytopenic purpura [J]. Eur J Haematol, 2007, 78(2): 139-143.
|
| 38 |
Sakakura M, Wada H, Tawara I, et al. Reduced CD4＋CD25＋ T cells in patients with idiopathic thrombocytopenic purpura [J]. Thromb Res, 2007, 120(2): 187-193.
|
| 39 |
Yu J, Heck S, Patel V, et al. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura [J]. Blood, 2008, 112(4): 1325-1328.
|
| 40 |
Yang Y, Xuan M, Zhang X, et al. Decreased IL-35 levels in patients with immune thrombocytopenia [J]. Hum Immunol, 2014, 75(8): 909-913.
|
| 41 |
Yilmaz H, Cakmak M, Ceydilek B, et al. Role of interlekin-35 as a biomarker in patients with newly diagnosed Hashimoto′s thyroiditis [J]. Endocr Regul, 2016, 50(2): 55-61.
|
| 42 |
Ozkan ZS, Deveci D, Simsek M, et al. What is the impact of SOCS3, IL-35 and IL17 in immune pathogenesis of recurrent pregnancy loss? [J]. J Matern Fetal Neonatal Med, 2015, 28(3): 324-328.
|
| 43 |
Ozkan ZS, Simsek M, Ilhan F, et al. Plasma IL-17, IL-35, interferon-gamma, SOCS3 and TGF-beta levels in pregnant women with preeclampsia, and their relation with severity of disease [J]. J Matern Fetal Neonatal Med, 2014, 27(15): 1513-1517.
|
| 44 |
Dantas AT, Goncalves SM, Pereira MC, et al. Increased IL-35 serum levels in systemic sclerosis and association with pulmonary interstitial involvement [J]. Clin Rheumatol, 2015, 34(9): 1621-1625.
|
| 45 |
Tang J, Lei L, Pan J, et al. Higher levels of serum interleukin-35 are associated with the severity of pulmonary fibrosis and Th2 responses in patients with systemic sclerosis [J]. Rheumatol Int, 2018, 38(8): 1511-1519.
|